OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 18,602 Cr.
- Current Price ₹ 1,626
- High / Low ₹ 1,800 / 1,163
- Stock P/E
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE -11.8 %
- ROE -45.6 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.52%
- Company has a low return on equity of -48.5% over last 3 years.
- Debtor days have increased from 73.5 to 117 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 21 | 128 | 39 | 172 | |
| 93 | 132 | 199 | 254 | |
| Operating Profit | -71 | -4 | -161 | -82 |
| OPM % | -334% | -3% | -415% | -48% |
| 1 | -128 | -526 | -143 | |
| Interest | 16 | 46 | 48 | 89 |
| Depreciation | 34 | 53 | 66 | 76 |
| Profit before tax | -121 | -231 | -800 | -391 |
| Tax % | 0% | -0% | 0% | 0% |
| -121 | -231 | -800 | -391 | |
| EPS in Rs | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 100% |
| TTM: | 344% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 59% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -49% |
| Last Year: | -46% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 4 |
| Reserves | 774 | 1,009 | 781 | 392 | 401 |
| 386 | 1,182 | 864 | 571 | 612 | |
| 96 | 248 | 365 | 459 | 266 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 1,283 |
| 633 | 1,231 | 1,361 | 863 | 972 | |
| CWIP | 431 | 490 | 334 | 188 | 43 |
| Investments | 0 | 0 | 4 | 20 | 11 |
| 195 | 722 | 314 | 356 | 257 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 1,283 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| -118 | -416 | -163 | -107 | |
| -207 | -692 | -68 | 511 | |
| 381 | 1,162 | 118 | -391 | |
| Net Cash Flow | 56 | 54 | -112 | 13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 |
| Inventory Days | 87 | 615 | 258 | |
| Days Payable | 762 | 420 | 163 | |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 |
| Working Capital Days | -1,085 | 271 | -1,953 | -259 |
| ROCE % | -3% | -12% | -12% |
Documents
Announcements
-
Board Meeting Intimation for Prior Intimation Of Board Meeting
1d - Board meeting on May 5 to approve audited results for quarter/year ended March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Schedule of intimation of investors call dated May 06,2025
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
26 Apr - Of newspaper advertisement for dispatch of postal ballot notice.
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 25 Apr
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
23 Apr - Regulatory filing on mandatory and actual debt borrowing for FY, including shortfall details.
Annual reports
No data available.
Concalls
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.